These same studies also revealed that the inhibition of glutamine synthetase can detrimentally impact the survival impact myeloma cell lines and can increase the cytotoxic effects of HDAC inhibitors, which are commonly used in multiple myeloma treatment [14]. The gene discussed is HDAC9; the disease is plasma cell myeloma.